Healthcare Services Group
HCSG
20.79
-0.34
-1.61%
Healthcare Services Group
US · HCSG
#3008 by market cap
Listed 1970
20.79
-0.34
-1.61%
Live - 5344 symbols - heartbeat 149s ago
· 2026-10-07 19:54
After-hours
20.79
0.00%
- Market cap
- 1.43B
- P/E (TTM)i
- 12.16
- P/Bi
- 2.75
- EPSi
- 0.81
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on HCSG?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.67, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.08% YoY
Margins
- Gross margin
- 13.03%
- Operating margin
- 3.04%
- Net margin
- 3.21%
Key ratios & quality
- PEG ratioi
- 0.61
- Altman Z-Scorei
- 6.67
PEG uses trailing P/E against the 3-year net income growth rate (19.92%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.00B | 1.84B | 1.76B | 1.64B | 1.69B | 1.67B | 1.72B | 1.84B |
| Gross profit | 234.44M | 227.90M | 267.99M | 230.57M | 193.31M | 214.75M | 228.09M | 239.41M |
| Selling & admin expenses | 136.60M | 150.02M | 141.58M | 166.43M | 149.52M | 166.77M | 174.82M | 183.61M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 97.84M | 77.88M | 126.41M | 64.13M | 43.79M | 47.97M | 53.27M | 55.80M |
| Pretax profit | 99.91M | 85.10M | 129.19M | 65.51M | 44.55M | 53.06M | 52.94M | 67.87M |
| Tax | 16.39M | 20.52M | 30.50M | 16.97M | 10.31M | 14.67M | 13.47M | 8.81M |
| Net profit | 83.52M | 64.58M | 98.68M | 48.54M | 34.24M | 38.39M | 39.47M | 59.06M |
| Basic EPS | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Diluted EPS | 1.12 | 0.87 | 1.32 | 0.65 | 0.46 | 0.52 | 0.53 | 0.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 447.66M | 458.49M | 464.34M | 466.68M | 462.77M | 470.81M |
| Gross profit | 67.97M | 2.96M | 96.41M | 72.07M | 75.83M | 74.79M |
| Selling & admin expenses | 46.43M | 44.51M | 46.82M | 45.83M | 43.57M | 45.69M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 21.54M | -41.56M | 49.58M | 26.24M | 32.27M | 29.10M |
| Pretax profit | 23.89M | -41.89M | 57.31M | 28.55M | 34.54M | 31.00M |
| Tax | 6.67M | -9.52M | 14.36M | -2.69M | 8.48M | 8.31M |
| Net profit | 17.23M | -32.37M | 42.95M | 31.24M | 26.06M | 22.70M |
| Basic EPS | 0 | 0 | 1 | 0 | 0 | 0 |
| Diluted EPS | 0.23 | -0.44 | 0.59 | 0.44 | 0.37 | 0.32 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 508.14M | 515.73M | 572.40M | 546.38M | 508.63M | 571.70M | 556.65M | 576.42M |
| Cash & ST investments | 102.39M | 118.04M | 264.34M | 185.19M | 121.48M | 147.46M | 107.31M | 167.96M |
| Inventory | 41.44M | 36.52M | 31.59M | 26.02M | 21.16M | 18.48M | 16.75M | 16.80M |
| Total assets | 692.60M | 722.59M | 785.03M | 777.53M | 720.84M | 790.65M | 802.77M | 794.25M |
| Total current liabilities | 163.39M | 148.65M | 162.26M | 191.13M | 189.01M | 216.93M | 192.55M | 170.38M |
| Short-term debt | 30.00M | 10.00M | -- | -- | 25.00M | 25.00M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 251,823,000.00 | 262,287,000.00 | 304,570,000.00 | 324,852,000.00 | 302,557,000.00 | 334,036,000.00 | 302,845,000.00 | 284,043,000.00 |
| Total equity | 440.78M | 460.31M | 480.46M | 452.68M | 418.28M | 456.62M | 499.93M | 510.21M |
| Retained earnings | 190.09M | 195.46M | 200.89M | 183.96M | 146.60M | 185.01M | 224.56M | 283.67M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 574.97M | 532.29M | 580.63M | 576.42M | 601.23M | 568.53M |
| Cash & ST investments | 114.81M | 134.49M | 177.46M | 167.96M | 178.61M | 164.72M |
| Inventory | 17.27M | 17.36M | 17.20M | 16.80M | 15.89M | 15.84M |
| Total assets | 822.96M | 802.20M | 804.30M | 794.25M | 814.85M | 820.86M |
| Total current liabilities | 198.75M | 213.93M | 195.64M | 170.38M | 193.37M | 188.12M |
| Short-term debt | -- | 8.30M | 7.64M | -- | 5.29M | 6.40M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 308,765,000.00 | 325,162,000.00 | 308,297,000.00 | 284,043,000.00 | 301,079,000.00 | 302,015,000.00 |
| Total equity | 514.20M | 477.04M | 496.00M | 510.21M | 513.77M | 518.84M |
| Retained earnings | 241.84M | 209.47M | 252.42M | 283.67M | 309.73M | 332.43M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 80.03M | 93.58M | 217.21M | 37.11M | -8.17M | 43.50M | 30.80M | 144.97M |
| Depreciation & amortization | 9.27M | 13.94M | 14.27M | 14.67M | 15.32M | 14.34M | 14.59M | 16.78M |
| Free cash flow | 75.09M | 89.21M | 212.87M | 31.42M | -13.38M | 38.09M | 24.47M | 139.15M |
| Dividends paid | -57.20M | -58.95M | -60.71M | -62.23M | -63.37M | -- | -- | -- |
| Stock buybacks / issuance | 89.00K | 90.00K | 93.00K | -21.44M | 106.00K | -11.28M | -5.02M | -61.59M |
| Ending cash balance | 26.03M | 27.33M | 139.33M | 70.79M | 26.28M | 54.33M | 60.13M | 130.77M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 27.50M | 28.79M | 71.29M | 17.39M | 43.73M | 21.87M |
| Depreciation & amortization | 3.88M | 5.00M | 4.03M | 3.87M | 3.81M | 3.52M |
| Free cash flow | 25.76M | 27.43M | 69.96M | 16.01M | 42.33M | 20.24M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -7.04M | -7.68M | -27.27M | -19.60M | -23.96M | -20.93M |
| Ending cash balance | 64.38M | 83.14M | 124.42M | 130.77M | 136.27M | 123.46M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.87 | 14.33 | 20.98 | 9.83 | 7.88 | 8.70 | 8.25 | 11.69 |
| ROA %i | 12.21 | 9.13 | 13.09 | 5.87 | 4.63 | 5.09 | 4.95 | 7.40 |
| ROIC %i | 18.44 | 13.94 | 20.70 | 9.81 | 7.79 | 9.26 | 9.07 | 11.76 |
| 5-year avg ROE %i | 19.24 | 20.55 | 20.69 | 17.89 | 14.69 | 12.47 | 11.25 | 9.40 |
| EBIT margin %i | 4.92 | 4.81 | 7.42 | 3.85 | 2.84 | 3.64 | 3.46 | 3.78 |
| FCF / sales %i | 3.74 | 4.85 | 12.09 | 1.91 | -- | 2.28 | 1.43 | 7.57 |
| Current ratioi | 3.11 | 3.47 | 3.53 | 2.86 | 2.69 | 2.64 | 2.89 | 3.38 |
| Quick ratioi | 2.72 | 3.09 | 3.21 | 2.55 | 2.46 | 2.45 | 2.54 | 2.95 |
| Debt / assetsi | 4.33 | 3.00 | 1.45 | 1.45 | 4.59 | 4.58 | 1.00 | 1.22 |
| LT debt / equityi | -- | 2.53 | 2.37 | 2.50 | 1.94 | 2.46 | 1.61 | 1.89 |
| Interest coveragei | -- | 25.60 | 95.02 | 45.64 | 16.09 | 7.75 | 9.22 | 43.95 |
| Revenue CAGR (3Y) %i | 11.70 | 5.61 | -1.84 | -6.40 | -2.81 | -1.71 | 1.47 | 2.82 |
| Net income CAGR (3Y) %i | 12.91 | -5.86 | 3.80 | -16.55 | -19.06 | -27.00 | -6.66 | 19.92 |
| FCF CAGR (3Y) %i | 8.76 | 35.38 | 356.82 | -25.20 | -- | -43.65 | -8.00 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.37 | 2.28 | 8.07 | 11.69 | 13.21 | 24.69 |
| ROA %i | 5.09 | 1.35 | 4.94 | 7.40 | 8.29 | 15.15 |
| ROIC %i | 8.93 | 2.64 | 8.03 | 11.76 | 13.11 | 24.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.47 | 1.08 | 3.12 | 3.78 | 4.32 | 8.21 |
| FCF / sales %i | 4.51 | 5.13 | 8.73 | 7.57 | 8.41 | 7.97 |
| Current ratioi | 2.89 | 2.49 | 2.97 | 3.38 | 3.11 | 3.02 |
| Quick ratioi | 2.52 | 2.14 | 2.59 | 2.95 | 2.70 | 2.60 |
| Debt / assetsi | 0.97 | 1.91 | 1.72 | 1.22 | 1.80 | 2.16 |
| LT debt / equityi | 1.55 | 1.48 | 1.25 | 1.89 | 1.82 | 2.18 |
| Interest coveragei | 12.48 | 5.41 | 23.70 | 43.95 | 51.65 | 87.47 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Dietary is the largest reported line at 54.72% of revenue, across 2 reported segments.
- Environmental Services (EVS) follows at 45.28%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Dietary54.72%
Environmental Services (EVS)45.28%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.